A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease
Joe W. Gray(University of Newcastle Australia), Helen L. Reeves(Newcastle upon Tyne Hospital), Gary Beale(Epistem (United Kingdom)), Derek Manas, Dipankar Chattopadhyay(University of Calcutta), Barry P. King(Newcastle University), Luca Miele(Agostino Gemelli University Polyclinic), Stephen Stewart(Freeman Hospital), Mark Hudson(The Open University), Christopher P. Day(Newcastle University), Gillian Patman(Newcastle University)
Cited by 72
Related Papers
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease†
|Hepatology|2009|1.4k
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
|Nature Genetics|2009|1.1k
Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients
|Diabetes Care|2007|989
The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution
|Cell|2020|602
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
|Journal of Clinical Investigation|2012|591